Key Takeaways
- Moderna shares jumped more than 16% following the publication of Phase 3 data in the New England Journal of Medicine for its mRNA flu vaccine (mRNA-1010), demonstrating superiority versus a standard-dose comparator vaccine in adults 50 years and older.
- Following Moderna’s Q1 2026 earnings report, three Wall Street firms upgraded their outlook: Evercore ISI boosted its price target to $50, Goldman Sachs increased to $49, and Piper Sandler launched coverage with a Buy recommendation.
- Headlines surrounding a hantavirus outbreak connected to a cruise voyage from Argentina to Cabo Verde temporarily drew attention to Moderna’s early-phase hantavirus research, though Wall Street analysts emphasize minimal commercial potential.
- The FDA has scheduled August 5 as the PDUFA target date for mRNA-1010, while applications remain under evaluation in Europe, Canada, and Australia.
- Pfizer and BioNTech discontinued patient recruitment for a significant U.S. COVID vaccine study in the 50–64 age group citing insufficient enrollment numbers.
Moderna shares were changing hands near $56 Thursday afternoon, representing a gain exceeding 16% during the session, propelled by robust clinical trial outcomes, multiple analyst upgrades, and brief investor focus on hantavirus-related news.
The primary catalyst was clear-cut: Phase 3 clinical trial findings for Moderna’s experimental mRNA-based influenza vaccine, designated mRNA-1010, appeared in the New England Journal of Medicine. The published results demonstrated the vaccine achieved its predetermined superiority endpoint when compared against a licensed standard-dose seasonal influenza vaccine in individuals aged 50 and above.
This represents a significant achievement. Demonstrating superior performance against an already-approved vaccine in a prestigious peer-reviewed publication strengthens Moderna’s regulatory submission as it approaches a critical FDA milestone.
The FDA has designated August 5 as the target action date under the Prescription Drug User Fee Act for mRNA-1010. Submissions are simultaneously undergoing regulatory assessment in Europe, Canada, and Australia, positioning this as a potentially global product launch if regulatory clearances are granted.
Wall Street support amplified the upward momentum. Evercore ISI increased its price objective from $35 to $50. Goldman Sachs elevated its target from $43 to $49. Piper Sandler launched coverage with a Buy recommendation. All three actions followed Moderna’s first-quarter 2026 financial results.
Hantavirus News Created Brief Volatility
A hantavirus cluster affecting travelers aboard a Dutch-registered cruise vessel sailing from Argentina to Cabo Verde temporarily boosted Moderna shares during morning trading. Eight individuals were infected, resulting in three fatalities, with five cases confirmed as Andes virus — the sole hantavirus variant capable of limited person-to-person transmission.
The World Health Organization assessed the public health threat as minimal. At Thursday’s press briefing, Dr. Maria Van Kerkhove stated unambiguously: “This is not the start of a COVID pandemic.”
Evercore ISI highlighted a Moderna partnership with Korea University focused on hantavirus research dating to 2023, but offered clear caution. The firm stated it identifies “no meaningful revenue opportunity” stemming from the outbreak-related headlines and emphasized that Moderna’s hantavirus program “remains very early stage.” The equity, analysts observed, “tends to trade on outbreak headlines well beyond the underlying commercial implications.”
Bottom line: while hantavirus news captured headlines, the influenza vaccine data and Wall Street upgrades provided the real momentum.
Cruise Operators Experienced Pressure
Cruise line equities declined on the hantavirus developments. Royal Caribbean decreased approximately 2% during the session, while Carnival posted a comparable decline. Norwegian Cruise Line Holdings fell nearly 3%. Viking Holdings and Lindblad Expeditions each declined roughly 2.5%.
Regarding competition, Pfizer and BioNTech suspended enrollment in a substantial U.S. COVID vaccine clinical trial focusing on adults between 50 and 64 years old, attributing the decision to inadequate participation. This development could strengthen Moderna’s comparative position in next-generation vaccine development.
Broader equity markets provided a favorable backdrop, with the S&P 500 advancing 0.71%, the Dow Jones Industrial Average rising 0.21%, and the Nasdaq Composite gaining 1.16%.
Moderna concluded the previous trading session at $48.79. The August 5 FDA decision date for mRNA-1010 now represents the next significant milestone for investors to monitor.
